FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

SPOTLIGHT: Investors, analysts not impressed with Pfizer


Investors and analysts are none too impressed with Pfizer's new strategies as outlined by CEO Jeffrey Kindler and other execs during an annual Wall Street update yesterday. The stock fell to within 50 cents of its 52-week low, and analysts expressed disappointment, boredom and frustration. They have been hoping--expecting--big changes from Kindler, and not unfairly, because he promised them. The one thing that might have set observers abuzz--a big acquisition--Kindler ruled out completely. Report

More stories about Pfizer   Mergers and Acqusitions   Jeffrey Kindler  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 12 + 68?
To combat spam, please solve the math question above.